Premium
Nuclear expression of the antiapoptotic protein survivin in malignant melanoma
Author(s) -
Ding Yiling,
Prieto Victor G.,
Zhang Peter S.,
Rosenthal Seth,
Smith Kathleen J.,
Skelton Henry G.,
Diwan A. Hafeez
Publication year - 2006
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.21727
Subject(s) - survivin , melanoma , medicine , polyclonal antibodies , pathology , tissue microarray , nevus , immunohistochemistry , cancer research , antibody , cancer , immunology
BACKGROUND Expression of the antiapoptotic protein survivin has been demonstrated in some melanocytic lesions and is believed to be required for melanoma cell viability. However, its diagnostic value in differentiating melanomas from nevi has not yet been examined. METHODS Tissue microarray blocks were constructed with paraffin‐fixed tissue of 19 nevi, 18 dysplastic nevi, 24 malignant melanomas, and 31 metastatic melanomas. Sections were then reacted with three antisurvivin antibodies (two monoclonal and one polyclonal) assessing labeling intensity (absent or weak, and moderate to strong) as well as the percentage of cells labeled (< 25%, ≥ 25%). RESULTS Of the antibodies evaluated, the polyclonal one was found to be the most sensitive. Nuclear immunoreactivity for survivin (i.e., ≥ 25% of cells exhibiting and/or at least moderately intense staining) was seen in a subset of melanomas but not in nevi or dysplastic nevi ( P < 0.05) CONCLUSIONS Survivin is variably expressed in the cytoplasm in the entire spectrum of melanocytic lesions, with nuclear expression detectable only in melanomas. These data may underscore the importance of nuclear survivin in progression to melanoma and may prove useful in the differential diagnosis of melanoma versus nevus. Cancer 2006. © 2006 American Cancer Society.